UNSPSC 51143209: Acamprosate calcium

This classification denotes a neuroprotective agent with the molecular formula 2C5H10NO4S.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59375N1D0U, chemically known as 1-propanesulfonic acid, 3-(acetylamino)-, calcium salt (2:1) but more generally known as acamprosate calcium, which bears US NIH Compound Identifier 155434. European Medicines Agency schedules Acamprosate calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00239MIG.

Most nations, for tariff and trade purposes, schedule acamprosate calcium under HS 29241900 and SITC 51471. As of Q4 2014, ACAMPROSATE CALCIUM remains US FDA's Preferred Term for this commodity. Acamprosate calcium bears US NLM identifiers UMLS ID C0592789 and NCI Concept Code C65209. SMILES: CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[CA+2].

UNSPSC 51143209 Acamprosate calcium is a Commodity code that nominally covers pharmaceutical products, but the recent state and local opportunities posted under this code show little alignment with acamprosate itself. Instead, the code has been applied to solicitations for naloxone (opioid-reversal medication) and to a broader state-level market-research inquiry into direct-to-manufacturer prescription fulfillment models. The mismatch suggests either miscoding at the point of posting or that the code is being used more broadly to capture pharmaceutical procurement activity in general. State and local health agencies—county public health departments and state health and human services commissions—are the primary issuing bodies under this code when activity does occur.

Recent opportunities include Seminole County, Florida issuing an IFB (Solicitation Number IFB60459723LAS, response deadline July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to a county community health building, and the Texas Health and Human Services Commission posting a Request for Information (RFI No. HHS0017013, response deadline April 3, 2026) to explore vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. Activity is concentrated in the Southeast and Southwest, with no clear pattern of repeated state or regional buyers under this specific code. The limited recent activity and the posted opportunities' divergence from the code's nominal pharmaceutical scope suggest that business development professionals should monitor this code for actual acamprosate or addiction-medicine procurement but should verify coding accuracy before committing resources to responses.